Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Non-Current Deferred Tax Liability: 2015-2021

Historic Non-Current Deferred Tax Liability for Assembly Biosciences (ASMB) over the last 3 years, with Sep 2021 value amounting to $2.5 million.

  • Assembly Biosciences' Non-Current Deferred Tax Liability changed negligibly% to $2.5 million in Q3 2021 from the same period last year, while for Sep 2021 it was $2.5 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $2.5 million for FY2020, which is negligibly% changed negligibly from last year.
  • According to the latest figures from Q3 2021, Assembly Biosciences' Non-Current Deferred Tax Liability is $2.5 million, which was down 0.00% from $2.5 million recorded in Q2 2021.
  • In the past 5 years, Assembly Biosciences' Non-Current Deferred Tax Liability registered a high of $3.3 million during Q4 2018, and its lowest value of $2.1 million during Q4 2017.
  • Over the past 3 years, Assembly Biosciences' median Non-Current Deferred Tax Liability value was $2.5 million (recorded in 2021), while the average stood at $2.7 million.
  • Per our database at Business Quant, Assembly Biosciences' Non-Current Deferred Tax Liability crashed by 80.79% in 2017 and then skyrocketed by 52.25% in 2018.
  • Assembly Biosciences' Non-Current Deferred Tax Liability (Quarterly) stood at $2.1 million in 2017, then spiked by 52.25% to $3.3 million in 2018, then dropped by 22.17% to $2.5 million in 2019, then remained steady at $2.5 million in 2020, then remained steady at $2.5 million in 2021.
  • Its last three reported values are $2.5 million in Q3 2021, $2.5 million for Q2 2021, and $2.5 million during Q1 2021.